Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 372Neoplasms 263Prostatic Neoplasms 188Lung Neoplasms 137Colorectal Neoplasms 128Head and Neck Neoplasms 76Colonic Neoplasms 67Pancreatic Neoplasms 63Carcinoma, Non-Small-Cell Lung 63Carcinoma, Hepatocellular 61Uterine Cervical Neoplasms 57Multiple Myeloma 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 53Neoplasm Metastasis 51Leukemia, Myeloid, Acute 50Brain Neoplasms 48Liver Neoplasms 44Rectal Neoplasms 42Melanoma 42Motor Activity 41Lymphoma, Non-Hodgkin 41Lymphoma 39Leukemia 38Pain 37Ovarian Neoplasms 36Hodgkin Disease 36Fatigue 34Depression 34Barrett Esophagus 34Lymphoma, Follicular 33

Interventions

Daptomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Has results × Soft Tissue Infections × Clear all
NCT00261807 2022-01-27

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

University of Maryland, Baltimore

Phase NA Completed
25 enrolled 7 charts
Lymphoid

Infections, Lymphoma, Follicular, Soft Tissue Infections, Fournier Gangrene, Fasciitis, Necrotizing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡